Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
View/ Open
Author
Tolaney, Sara
Boucher, Yves
Duda, Dan
Martin, John
Seano, Giorgio
Ancukiewicz, Marek
Barry, William
Goel, Shom
Lahdenrata, Johanna
Isakoff, Steven
Yeh, Eren
Jain, Saloni
Golshan, Mehra
Brock, Jane
Snuderl, Matija
Winer, Eric
Krop, Ian
Jain, Rakesh
Published Version
https://doi.org/10.1073/pnas.1518808112Metadata
Show full item recordCitation
Tolaney, Sara M., Yves Boucher, Dan G. Duda, John D. Martin, Giorgio Seano, Marek Ancukiewicz, William T. Barry, et al. 2015. “Role of Vascular Density and Normalization in Response to Neoadjuvant Bevacizumab and Chemotherapy in Breast Cancer Patients.” Proceedings of the National Academy of Sciences 112 (46): 14325–30. https://doi.org/10.1073/pnas.1518808112.Abstract
Preoperative bevacizumab and chemotherapy may benefit a subset of breast cancer (BC) patients. To explore potential mechanisms of this benefit, we conducted a phase II study of neoadjuvant bevacizumab (single dose) followed by combined bevacizumab and adriamycin/cyclophosphamide/paclitaxel chemotherapy in HER2-negative BC. The regimen was well-tolerated and showed a higher rate of pathologic complete response (pCR) in triple-negative (TN) BC (11/21 patients or 52%, [95% confidence interval (CI): 30,74]) than in hormone receptor-positive (HR) BC [5/78 patients or 6% (95% CI: 2,14)]. Within the HRBCs, basal-like subtype was significantly associated with pCR (P = 0.007; Fisher exact test). We assessed interstitial fluid pressure (IFP) and tissue biopsies before and after bevacizumab monotherapy and circulating plasma biomarkers at baseline and before and after combination therapy. Bevacizumab alone lowered IFP, but to a smaller extent than previously observed in other tumor types. Pathologic response to therapy correlated with sVEGFR1 postbevacizumab alone in TNBC (Spearman correlation 0.610, P = 0.0033) and pretreatment microvascular density (MVD) in all patients (Spearman correlation 0.465, P = 0.0005). Moreover, increased pericyte-covered MVD, amarker of extent of vascular normalization, after bevacizumab monotherapy was associated with improved pathologic response to treatment, especially in patients with a high pretreatment MVD. These data suggest that bevacizumab prunes vessels while normalizing those remaining, and thus is beneficial only when sufficient numbers of vessels are initially present. This study implicates pretreatment MVD as a potential predictive biomarker of response to bevacizumab in BC and suggests that new therapies are needed to normalize vessels without pruning.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41482962
Collections
- HMS Scholarly Articles [18113]
Contact administrator regarding this item (to report mistakes or request changes)